Related Experiment Video
Updated: Apr 9, 2026
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
Comparison between urinary 11-dehydrothromboxane B2 detection and platelet Light Transmission Aggregometry (LTA)
Tengfei Liu1, Jingwei Zhang1, Xiahuan Chen1
1Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
Insights
Light Transmission Aggregometry (LTA) identified high on aspirin platelet reactivity (HAPR) predicting cardiovascular events in elderly Chinese patients with coronary artery disease (CAD). Urinary 11-dehydrothromboxane B2 (11dhTXB2) assay did not correlate with outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Biochemistry
Background:
- Aspirin is a cornerstone in cardiovascular disease prevention.
- Assessing aspirin response is crucial for optimizing treatment efficacy.
- Elderly Chinese patients with coronary artery disease (CAD) represent a specific population for study.
Purpose of the Study:
- To compare urinary 11-dehydrothromboxane B2 (11dhTXB2) and platelet Light Transmission Aggregometry (LTA) assays for evaluating aspirin response.
- To investigate the clinical significance of these assays in predicting cardiovascular events in elderly Chinese CAD patients.
Main Methods:
- Urinary 11dhTXB2 levels and arachidonic acid-induced (AA) platelet aggregation via LTA were measured.
- High on aspirin platelet reactivity (HAPR) was defined based on assay-specific thresholds.
- Patients were followed for 12 months to record cardiovascular events.
Main Results:
- A poor correlation (r=0.063) and agreement (kappa=0.053) were observed between the 11dhTXB2 and LTA assays for classifying HAPR.
- HAPR identified by LTA was associated with a significantly higher incidence of cardiovascular events (22.5% vs 10.6%, P=0.039).
- HAPR determined by urinary 11dhTXB2 did not significantly correlate with cardiovascular outcomes.
Conclusions:
- Light Transmission Aggregometry (LTA) appears more clinically relevant than urinary 11dhTXB2 for predicting cardiovascular events in elderly Chinese patients with CAD on aspirin therapy.
- Discrepancies between aspirin response assays highlight the need for careful selection in clinical practice.
- Further research may be warranted to elucidate the optimal method for assessing aspirin response in diverse patient populations.
Abstract:
Aspirin is widely used in the primary and secondary prevention of cardiovascular diseases. The aim of our study was to compare between two established methods of aspirin response, urinary 11-dehydrothromboxane B2 (11dhTXB2) and platelet Light Transmission Aggregometry (LTA) assays in elderly Chinese patients with coronary artery disease (CAD), and to investigate the clinical significance of both methods in predicting cardiovascular events. Urinary 11dhTxB2 assay and arachidonic acid-induced (AA, 0.5mg/ml) platelet aggregation by Light Transmission Aggregometry (LTAAA) assay were measured to evaluate aspirin responses. High-on aspirin platelet reactivity (HAPR) was defined as urinary 11dhTxB2>1500pg/mg or AA-induced platelet aggregation≥15.22%-the upper quartile of our enrolled population. The two tests showed a poor correlation for aspirin inhibition (r=0.063) and a poor agreement in classifying HAPR (kappa=0.053). With a mean follow-up time of 12months, cardiovascular events occurred more frequently in HAPR patients who were diagnosed by LTA assay as compared with no-HAPR patients (22.5% versus 10.6%, P=0.039, OR=2.45, 95% CI=1.06-5.63). However, the HAPR status, as determined by urinary 11dTXB2 measurement, did not show a significant correlation with outcomes.
